BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19167214)

  • 21. Immunotherapy for pancreatic cancer - science driving clinical progress.
    Laheru D; Jaffee EM
    Nat Rev Cancer; 2005 Jun; 5(6):459-67. PubMed ID: 15905855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
    Dang Y; Disis ML
    Ann N Y Acad Sci; 2009 Sep; 1174():81-7. PubMed ID: 19769740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and development of therapeutic cancer vaccines.
    Acres B; Limacher JM; Bonnefoy J
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):185-92. PubMed ID: 17436554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunologic approaches to ovarian cancer treatment.
    Sabbatini P; Odunsi K
    J Clin Oncol; 2007 Jul; 25(20):2884-93. PubMed ID: 17617519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer vaccines: toward the next revolution in cancer therapy.
    Emens LA
    Int Rev Immunol; 2006; 25(5-6):259-68. PubMed ID: 17169776
    [No Abstract]   [Full Text] [Related]  

  • 28. Gene-modified cellular vaccines: technologic aspects and clinical problems.
    Mackiewicz J; Mackiewicz A
    Transplant Proc; 2010 Oct; 42(8):3287-92. PubMed ID: 20970673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine and immuno-gene therapy for solid tumors.
    Li CY; Huang Q; Kung HF
    Cell Mol Immunol; 2005 Apr; 2(2):81-91. PubMed ID: 16191413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.
    Brichard VG; Lejeune D
    Vaccine; 2007 Sep; 25 Suppl 2():B61-71. PubMed ID: 17916463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for cancer: focusing on developing treatments rather than drugs.
    Sznol M
    Curr Opin Investig Drugs; 2001 Jul; 2(7):957-8. PubMed ID: 11757798
    [No Abstract]   [Full Text] [Related]  

  • 32. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
    Stebbing J; Wood C; Atkins M; Bukowski R; Litwin S; Bower M; Parsa A; Levitsky H
    Cancer; 2008 Mar; 112(5):955-61. PubMed ID: 18286505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigens for cancer immunotherapy.
    Neller MA; López JA; Schmidt CW
    Semin Immunol; 2008 Oct; 20(5):286-95. PubMed ID: 18951039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
    Brockstedt DG; Dubensky TW
    Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines: an innovative approach to treating cancer.
    Pazdur MP; Jones JL
    J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).
    Finke LH; Wentworth K; Blumenstein B; Rudolph NS; Levitsky H; Hoos A
    Vaccine; 2007 Sep; 25 Suppl 2():B97-B109. PubMed ID: 17916465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The capacity of the immune system to control cancer.
    Håkansson L
    Eur J Cancer; 2009 Aug; 45(12):2068-70. PubMed ID: 19608409
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future directions for vaccine-based therapies.
    Vieweg J
    Urol Oncol; 2006; 24(5):448-55. PubMed ID: 16962498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.